journal article·2025-12Open access

Lipid nanoparticle-mediated mRNA/siRNA dual-bioengineered dendritic cell vaccines combined of PD-1/PD-L1 blockade for boosting tumor immunotherapy

Dong Yang, Jing Zhan, Ling Miao, Chuan He, Hong Xu

Abstract

DC vaccines occupy a pivotal position in the realm of cancer treatment, leveraging the immune system to precisely target and effectively eliminate tumor cells. However, current challenges in tumor DC vaccine development include issues such as limited efficacy and potential upregulation of immunosuppressive molecules like PD-L1 on tumor cells. Herein, we employed microfluidic technology to fabricate lipid nanoparticles (LNPs) that simultaneously encapsulate OVA mRNA (mOVA), encoding the model antigen OVA, and siRNA targeting PD-L1. The LNP/mOVA/siPD-L1 nanoparticles were utilized to transfect bone marrow-derived dendritic cells (BMDCs) to construct dual-bioengineered DC vaccines. Subsequently, the efficacy of the dually bioengineered DC vaccines was verified in both prophylactic and therapeutic tumor vaccine models. The upregulation of PD-L1 protein expression on the surface of tumor cells was further blocked by combination of anti-PD-L1 antibody therapy. Notably, the combined therapy achieved complete tumor suppression and the rechallenge experiments demonstrated the tumor immune memory effect induced by the combined therapy, highlighting its potential to elicit long-lasting immunity against cancer. Overall, our findings suggest that this combined therapy holds significant promise for the treatment, metastasis prevention, and recurrence management of tumors, with potential clinical application value in the future.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (43)

Show source-provided references
1. Nanomaterials for T-cell cancer immunotherapy10.1038/s41565-020-00822-y ↗
2. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways10.1038/s41571-021-00552-7 ↗
3. Recent progress in dendritic cell-based cancer immunotherapy10.3390/cancers13102495 ↗
4. Advances in dendritic cell vaccination therapy of cancer10.1016/j.biopha.2023.114954 ↗
5. Dendritic cells in cancer immunology and immunotherapy10.3390/cancers16050981 ↗
6. Dendritic cells in cancer immunology and immunotherapy10.1038/s41577-019-0210-z ↗
7. Trial watch: dendritic cell (DC)-based immunotherapy for cancer10.1080/2162402X.2022.2096363 ↗
8. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine10.1158/1078-0432.CCR-10-3126 ↗
9. Antitumour dendritic cell vaccination in a priming and boosting approach10.1038/s41573-020-0074-8 ↗
10. Lipid Nanoparticle-mRNA engineered dendritic cell based adoptive cell therapy enhances cancer immune response10.1002/smtd.202400633 ↗
11. Dendritic cell subsets and implications for cancer immunotherapy
12. Development of mannosylated lipid nanoparticles for mRNA cancer vaccine with high antigen presentation efficiency and immunomodulatory capability10.1002/anie.202318515 ↗
13. Strategies to reduce the risks of mRNA drug and vaccine toxicity10.1038/s41573-023-00859-3 ↗
14. Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns10.1038/s41551-021-00795-w ↗
15. Small extracellular vesicles carrying reovirus, tumor antigens, interferon-beta, and damage-associated molecular patterns for efficient tumor treatment10.1016/j.jconrel.2024.07.079 ↗
16. Blood clot scaffold loaded with liposome vaccine and siRNAs targeting PD-L1 and TIM-3 for effective DC activation and cancer immunotherapy10.1021/acsnano.2c10797 ↗
17. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells10.1038/s41551-021-00800-2 ↗
18. The hallmarks of cancer immune evasion10.1016/j.ccell.2024.09.010 ↗
19. PD-L1 siRNA incorporation into a cationic liposomal tumor mRNA vaccine enhances cytotoxic T cell activation and prevents immune evasion
20. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy
21. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy
22. Anion receptor-mediated multicomponent synergistic self-assembly of porphyrin for efficient phototherapy to elicit tumor immunotherapy10.1016/j.nantod.2022.101579 ↗
23. A Versatile nanovaccine enhancement strategy based on suction-inspired physical therapy10.1021/acsnano.3c10623 ↗
24. A snapshot of the PD-1/PD-L1 pathway10.7150/jca.57334 ↗
25. A comprehensive strategy based on high clinical translational nanosystem for programmable immunotherapy of triple negative breast cancer10.1002/adma.202314309 ↗
26. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
27. Engineering LNPs with polysarcosine lipids for mRNA delivery
28. beta-catenin mRNA encapsulated in SM-102 lipid nanoparticles enhances bone formation in a murine tibia fracture repair model
29. Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings10.1016/j.jconrel.2024.07.052 ↗
30. A polymeric mRNA vaccine featuring enhanced site-specific mRNA delivery and inherent STING-stimulating performance for tumor immunotherapy10.1002/adma.202410998 ↗
31. Rehmannia glutinosa polysaccharide induces maturation of murine bone marrow derived dendritic cells (BMDCs)10.1016/j.ijbiomac.2012.12.005 ↗
32. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
33. Optimized circular RNA vaccines for superior cancer immunotherapy10.7150/thno.104698 ↗
34. Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade
35. A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel10.1016/j.actbio.2023.08.010 ↗
36. Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance10.1126/sciadv.ado6342 ↗
37. Prognostic role of serum cytokines level in non-small cell lung cancer patients with anti-PD-1 and chemotherapy combined treatment
38. Co-delivery of dendritic cell vaccine and anti-PD-1 antibody with cryomicroneedles for combinational immunotherapy10.1002/btm2.10457 ↗
39. Research progress on dendritic cell vaccines in cancer immunotherapy10.1186/s40164-022-00257-2 ↗
40. Recent advances in experimental dendritic cell vaccines for cancer10.3389/fonc.2021.730824 ↗
41. An integrated polymeric mRNA vaccine without inflammation side effects for cellular immunity mediated cancer therapy10.1002/adma.202207471 ↗
42. mRNA vaccine for cancer immunotherapy10.1186/s12943-021-01335-5 ↗
43. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy10.1038/nnano.2017.113 ↗